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Abstract: Despite the high prevalence of subclinical sleep disturbances, existing treatments are
either potent prescription medications or over-the-counter supplements with minimal scientific
support and numerous side effects. However, preliminary evidence shows that polyphenols such
as rosmarinic acid and epigallocatechin gallate can support healthy sleep without significant side
effects. Therefore, the present study examined whether a polyphenol botanical blend (PBB) could
improve sleep and/or daytime functioning in individuals with subclinical sleep disturbances. A total
of 89 individuals completed a double-blind, randomized trial of daily treatment with PBB (n = 43)
or placebo (n = 46) 30 min before bed for 30 days. Participants were monitored for changes in sleep
(by sleep diary and an activity tracker), mood, and neurocognitive functioning. After 30 days, PBB
improved diary sleep quality (p = 0.008) and reduced insomnia severity (p = 0.044) when compared
to placebo. No other changes in sleep outcomes were observed. Additionally, PBB did not impair
neurocognitive functioning, and some improvement was noted in vigilant attention, working memory,
and risk assessment. Among individuals with subclinical sleep disturbances, PBB improved sleep
quality, insomnia severity, and neurocognitive functioning over placebo. These findings indicate that
polyphenol compounds may be useful for improving certain aspects of sleep without compromising
neurocognitive functioning.
Keywords: nutrition; sleep quality; polyphenol; cognition; dietary supplement
1. Introduction
Sleep disturbances are associated with impaired memory, cognitive dysfunction, and
emotional dysregulation [1–3]. For example, insomnia disorder is a common cause of
disrupted sleep and affects as many as 10 to 20% of the U.S. population [4]. However,
nearly half of adults experience transient insomnia [5], indicating that broad swathes of the
population are vulnerable to sleep disturbances that degrade physical and mental health.
Unfortunately, few interventions exist for individuals with subclinical sleep distur-
bances. While cognitive behavioral therapy for insomnia is the recommended first-line
treatment for insomnia due to its efficacy and minimal side effects [6,7], there are not
enough trained therapists to treat individuals with chronic insomnia, let alone subclinical
sleep problems [8]. Consequently, many patients seek prescription antidepressants and
hypnotics, which are heavily sedating, less effective, have more side effects, and can result
in long-term dependence, or over-the-counter sleep aids such as diphenhydramine or
doxylamine, which can result in cognitive impairments and daytime sleepiness [9–11].
Herbal supplements are also commonly used, such as valerian root (Valeriana officinalis),
lemon balm (Melissa officinalis), and chamomile (Matricaria recutita and Chamaemelum nobile).
Int. J. Environ. Res. Public Health 2021, 18, 3044. https://doi.org/10.3390/ijerph18063044 https://www.mdpi.com/journal/ijerph
Int. J. Environ. Res. Public Health 2021, 18, 3044 2 of 11
However, the evidence for such substances is usually derived from small, uncontrolled
studies lacking valid measures of sleep [12,13], and complaints of next-day grogginess,
dizziness, headaches, and nausea are common [14].
By contrast, emerging evidence indicates that polyphenols, such as rosmarinic acid
(RA) and epigallocatechin gallate (EGCG), may be effective sleep aids [15–18]. RA has
potent antioxidant effects in the brain, thus providing neuroprotective benefits, and may af-
fect sleep by modulating GABA and acetylcholine [16,17,19–22], while EGCG can attenuate
corticosterone release to downregulate the hypothalamic–pituitary–adrenal axis to provide
anxiolytic and hypnotic effects [15,23]. Dietary intake of polyphenols, including RA and
EGCG, is associated with improved sleep quality in healthy adults [24], as well as reduced
anxiogenic behavior and increased sleep time [25]. Thus, polyphenol compounds may be
effective at improving sleep without the negative side effects of other pharmacological
treatments.
Therefore, the present randomized placebo-controlled trial evaluated a polyphenol
botanical blend (PBB) as a sleep aid in individuals with minor sleep disturbances. The
primary hypotheses were that PBB supplementation would improve sleep onset latency, as
well as percentage of time in rapid-eye movement (REM) sleep due to hypothesized cholin-
ergic effects. The secondary hypotheses were that the use of PBB would improve other
aspects of sleep, such as sleep efficiency, sleep quality, or insomnia symptoms. Additional
analyses explored possible improvements in mood and neurocognitive functioning.
2. Materials and Methods
2.1. Overview
A 30-day double-blind, randomized, 1-to-1 placebo-controlled trial was conducted
to compare the effects of daily PBB supplementation on sleep and daytime functioning.
Subjects were assessed at 0-, 7-, and 30-days post randomization. Sleep was monitored
by sleep diaries and commercial activity trackers throughout the trial. This study was ap-
proved by the University of Arizona Institutional Review Board, conducted in accordance
with the Declaration of Helsinki, and registered with clinicaltrials.gov (NCT03567343). All
subjects provided informed consent prior to randomization.
2.2. Participants
Subject recruitment occurred by self-referral, social media, and flyer advertising in
Tucson, Arizona, USA. Participants were aged 22–50, in general good health, had a body
mass index between 18.5 and 29.9 kg/m2, and had not used nicotine in the past 6 months.
A score of 3 or higher on the Pittsburgh Sleep Quality Index was required for participation.
Participants were excluded if they had an active infection, uncontrolled hypertension,
a major psychiatric disorder as determined by the Mini International Neuropsychiatric
Inventory [26], a history of cancer within 5 years, a history of unconventional sleep pattern,
a diagnosed sleep disorder, or a chronic medical condition that could affect energy/fatigue
levels. Participants were also excluded if they were currently experiencing a major depres-
sive episode as determined by current Patient Health Questionnaire–9 [27] score, were
allergic to study products, consumed more than 400 mg of caffeine per day in the past
2 weeks, had used any psychotropic medications, stimulants, cannabis, non-registered drug
products, or illicit substances in the past 4 weeks, were at risk of drug or alcohol abuse, or
had used any sleep aids in the past 2 weeks. Finally, women who were pregnant, planning
to be pregnant, lactating, or unwilling to use a medically approved form of contraception
were excluded.
2.3. Procedures
This study took place between May 2017 and September 2018. A final study sample of
N = 100 (50 per group) was calculated based on proprietary pilot data conducted by the
study sponsor. PBB and placebo were packaged into identical capsules and bottles, masked,
and sent to the investigative site. The PBB is a 485 mg dose containing at least 120 mg
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polyphenols (and at least 65 mg rosmarinic acid and epigallocatechin gallate), and no more
than 4.85 mg of caffeine (≤1%) per dose. Once participants were screened as eligible and
provided informed consent, they were randomized to either PBB or placebo using random
number assignment (rand function in Excel) and sequentially numbered bottles. Study
staff involved in enrollment, data collection, and analysis were not involved in generating
the randomization sequence and were unaware of participants’ group status until after the
trial was complete. Similarly, participants were blinded to their treatment status. Once
randomized, participants were provided with an activity tracker (Fitbit Charge 2, Fitbit,
San Francisco, CA, USA) and directed to complete a daily sleep diary. Participants were
instructed to take the supplement 30 min before bedtime starting on Day 3 (to allow for
pre-treatment baseline data collection), and to maintain a consistent diet throughout the
study period. Additionally, alcohol consumption was limited to ≤14 drinks per week, no
more than 4 drinks at a time, and no more than 1 drink within 4 h of bedtime. Caffeine
consumption was limited to no more than 4 servings per day and no caffeine within 6 h of
bedtime, while vigorous physical activity was prohibited within 2 h of bedtime.
2.4. Measures
Sleep diary data were used to calculate daily total sleep time, sleep onset latency,
wake after sleep onset, sleep efficiency, and daily sleep quality and morning drowsiness.
Sleep diary items were based on the Consensus Sleep Diary [28]. Activity tracker data
were used to calculate daily total sleep time, sleep efficiency, and percent of light, deep,
and REM sleep, as these devices have demonstrated validity for estimating sleep and
wake, and moderate accuracy for sleep staging, relative to polysomnography [29,30]. Then,
daily values were averaged across weeks. The primary outcomes were sleep onset latency
(measured by sleep diary) and percentage of REM sleep.
On Days 0, 7, and 30, participants completed an assessment battery. This battery
included the Perceived Stress Scale (PSS) [31] to assess overall stress levels, the Profile of
Mood States (POMS) [32] to assess current mood, the Insomnia Severity Index (ISI) [33]
to assess overall insomnia symptom severity, the Center for Epidemiological Studies
Depression Scale (CESD) [34] to assess depressive symptoms, and the Pittsburgh Sleep
Quality Index (PSQI) [35] to assess overall sleep quality. Participants completed the
JoggleResearch neurocognitive battery [36], which included the N-back test of working
memory, a Visual Object Learning Task (VOLT) to assess visual learning and spatial working
memory, a Motor Praxis Task (MPT) to assess sensory motor speed, an Abstract Matching
task (AM), a Line Orientation Task (LOT), a Digital Symbol Substitution Task (DSST) for
complex scanning and visual tracking, and a Balloon Analog Risk Task (BART) to assess
risk-decision making, as well as a touchscreen Psychomotor Vigilance Task (PVT) [37]
to quantify vigilant attention. At the end of the study (Day 30), unused investigational
product was bought back to the investigators to determine subject adherence.
2.5. Statistical Analyses
All statistical analyses were conducted in R (v4.0.3, R Foundation for Statistical Com-
puting, Vienna, Austria) using the ‘lme4’ and ‘lmerTest’ packages [38,39]. The primary
outcomes were sleep onset latency measured by sleep diary and percentage of REM sleep
measured by the activity tracker. Secondary outcomes included sleep diary total sleep
time, wake after sleep onset, sleep efficiency, and sleep quality; activity tracker total sleep
time, sleep efficiency, percentage of light, deep, and REM sleep; ISI, POMS, PSS, CESD,
and PSQI scores; PVT attentional lapses and median reaction times; and neurocognitive
functioning measured by the JoggleResearch battery. Pre–post comparisons were made
using t-tests and chi-squared tests, while linear mixed-effects models assessed group, time,
and group by time effects on study outcomes. Sleep diary and activity tracker outcomes
were assessed 5 times (baseline, weeks 1–4), so there were enough degrees of freedom
for models to include random intercepts and slopes. However, other outcomes were only
assessed 3 times (baseline, day 7, day 30), and so those models only included random
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intercepts. All models were adjusted for sex and age, and significance was determined by
Wald tests. Results are presented as mean (standard deviation) or N (percent) for summary
statistics or beta coefficient (95% confidence interval) for regression models.
3. Results
3.1. Recruitment and Dropout
Recruitment and study completion are depicted in Figure 1. After screening 517 in-
dividuals, 105 subjects were randomized into the study. Of these, 96 subjects (91.4%)
completed the study, although seven individuals (6.7%) were excluded due to data errors
or adherence issues. This yielded a final sample of 89 participants (84.8%), with 43 receiv-
ing PBB and 46 receiving placebo. However, sleep data for one individual in the placebo
group were unavailable due to a data error, so sleep outcomes were evaluated for N = 45
participants in the placebo group.
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3.2. Sample Characteristics
The mean participant age was 31.5 (SD 8.1) years old, and the sample was 60% female.
There were no differences between groups by age, sex, body mass index (BMI), or for any
sleep diary variables. Activity tracker variables also showed no baseline group differences
except for REM sleep, with the PBB group showing greater percentage REM than placebo
(21.6 vs. 18.0, p = 0.022). These data are presented in Table 1. The subclinical sleep
disturbances reported in the sample ranged across all elements of the PSQI except for use
of a medication for sleep, which was minimal (Table S1).
Table 1. Baseline characteristics for the sample.
Characteristic Placebo PBB 1 p-value
N 46 43
Age 32.85 (8.62) 29.91 (7.17) 0.085
Sex >0.9
Male 18 (40%) 17 (40%)
Female 28 (60%) 26 (60%)
Race/Ethnicity 0.048
White 25 (54.4%) 30 (69.8%)
Black 3 (6.5%) 2 (4.7%)
Hispanic 10 (21.7%) 10 (23.3%)
Asian 8 (17.4%) 0 (0%)
Native American 0 (0%) 1 (2.3%)
BMI 24.4 (4.9) 23.9 (3.5) 0.6
Sleep Diary Placebo PBB p-value
Sleep Onset Latency (min) 14.02 (13.13) 14.94 (10.24) 0.7
Total Sleep Time (min) 406.08 (71.45) 408.33 (72.00) 0.9
Wake After Sleep Onset (min) 21.56 (19.88) 20.14 (18.28) 0.7
Sleep Efficiency (%) 83.09 (11.55) 83.57 (9.24) 0.8
Sleep Quality 6.62 (1.27) 6.37 (1.05) 0.3
Morning Refreshed 5.62 (2.01) 5.43 (2.02) 0.7
Morning Sleepiness 5.32 (1.79) 5.57 (1.84) 0.5
Activity Tracker Placebo PBB p-value
Total Sleep Time (min) 398.07 (70.65) 395.59 (67.38) 0.9
Light Sleep (%) 53.82 (16.49) 56.09 (9.01) 0.5
Deep Sleep (%) 15.68 (8.75) 17.30 (4.21) 0.3
REM Sleep (%) 18.03 (6.81) 21.60 (6.43) 0.022
Sleep Efficiency (%) 88.52 (2.66) 88.52 (2.10) >0.9
1 PBB: Polyphenol Botanical Blend; Data are presented as Mean (SD) or N (%); Statistical tests performed: t-test;
chi-square test of independence.
3.3. Sleep Outcomes
Pre–post comparisons and linear mixed-effects model results for the sleep outcomes
are presented in Table 2. There were no pre–post differences or significant effects of time
(p > 0.05) or group by time (p > 0.05) for sleep onset latency or percentage of REM sleep.
However, there was a significant group by time effect for sleep quality (p = 0.008), where
the PBB group showed a greater increase in sleep quality than placebo. This is shown in
Figure 2A.
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Table 2. Sleep diary and activity tracker outcomes.
Outcome Placebo (n = 45) PBB (n = 43) Linear Mixed-Effect Modeling †
Sleep Diary Pre Post Pre Post Time Group by Time
Sleep Onset Latency (min) 14.02 (13.13) 11.73 (10.23) 14.94 (10.24) 12.66 (7.62) −0.53 (−1.3, 0.19) 0.01 (−1.0, 1.0)
Total Sleep Time (min) 406.08 (71.45) 425.36 (52.09) 408.33 (72.00) 428.54 (58.48) 6.0 (2.0, 10) ** −0.41 (−6.2, 5.3)
Wake After Sleep Onset
(min) 21.56 (19.88) 18.03 (18.19) 20.14 (18.28) 16.15 (18.59) −1.0, (−2.1, 0.08) 0.06 (−1.5, 1.6)
Sleep Efficiency (%) 83.09 (11.55) 87.71 (6.36) 83.57 (9.24) 86.42 (8.31) 1.2 (0.52, 1.9) *** −0.49 (−1.5, 0.48)
Sleep Quality 6.62 (1.27) 7.02 (1.03) 6.37 (1.05) 7.33 (1.09) *** 0.10 (0.02, 0.17) * 0.11 (0.01, 0.22) *
Morning Refreshed 5.62 (2.01) 6.51 (1.56) * 5.43 (2.02) 6.60 (1.63) ** 0.18 (0.06, 0.30) ** 0.05 (−0.12, 0.23)
Morning Sleepiness 5.32 (1.79) 4.74 (1.39) * 5.57 (1.84) 4.56 (1.68) ** −0.13 (−0.24, −0.02) * −0.06 (−0.22, 0.09)
Actigraphy Pre Post Pre Post Time Group by Time
REM Sleep (%) 18.03 (6.81) 19.67 (5.79) 21.60 (6.43) 21.61 (5.10) 0.26 (−0.16, 0.67) −0.06 (−0.66, 0.54)
Total Sleep Time (min) 398.07 (70.65) 408.96 (48.17) 395.59 (67.38) 425.53 (40.97) * 4.3 (−0.35, 8.9) 5.2 (−1.4, 12)
Light Sleep (%) 53.82 (16.49) 53.46 (11.50) 56.09 (9.01) 56.26 (8.06) −0.32 (−2.0, 1.3) 0.75 (−1.7, 3.2)
Deep Sleep (%) 15.68 (8.75) 15.57 (4.06) 17.30 (4.21) 16.37 (3.42) −0.12 (−0.59, 0.35) 0.10 (−0.59, 0.78)
Sleep Efficiency (%) 88.52 (2.66) 88.32 (1.79) 88.52 (2.10) 88.29 (1.48) 0.00 (−0.16, 0.16) −0.03 (−0.26, 0.20)
* p < 0.05 ** p < 0.01, *** p < 0.001. Pre–post data are compared within-groups. † Models adjusted for sex and age with random slopes and
intercepts. Pre–post data are presented as mean (SD); regression outcomes are presented as β coefficients (95% CI).
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Figure 2. Mean (± SE) plots for outcomes with significant group by time effects, including sleep diary sleep quality (A), ISI
score (B), lapses (C), PVT median reaction time (D), N-back accuracy (E), and BART optimal pumps difference (F). Tests of
significance are between-group t-tests. * p < 0.05. ISI: Insomnia Severity Index, PBB: proprietary blend of botanical extracts,
PVT: Psychomotor Vigilance Task, BART: Balloon Analogue Risk Task.
3.4. Questionnaire Outcomes
Pre–post comparisons and linear mixed-effects model results for questionnaire out-
comes are presented in Table 3. There was a significant group by time effect for ISI score
(p = 0.044), where the PBB group decreased significantly over placebo. These data are
presented in Figure 2B.
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Table 3. Pre–post changes and linear mixed-effects model results for questionnaire outcomes.
Treatment Group: Placebo (n = 46) PBB (n = 43) Linear Mixed-Effect Models †
Questionnaires Pre Post Pre Post Time Group by Time
Pittsburgh Sleep Quality Index 5.20 (2.41) 5.30 (2.11) 5.44 (2.91) 5.21 (2.24) 0.03 (−0.43, 0.50) −0.15 (−0.82, 0.52)
Center for Epidemiological Studies
Depression Scale 3.91 (3.43) 4.54 (4.55) 5.26 (4.62) 5.77 (5.59) 0.36 (−0.42, 1.1) 0.10 (−1.2, 1.0)
Perceived Stress Scale 12.96 (6.25) 14.35 (5.73) 14.91 (5.44) 15.28 (6.29) 0.70 (−0.17, 1.6) −0.51 (−1.8, 0.73)
Insomnia Severity Index 4.74 (3.81) 5.70 (3.88) 6.07 (4.85) 5.12 (4.18) 0.48 (−0.14, 1.1) −1.0 (−2.0, −0.03) *
Profile of Mood States
Total Mood Disturbance −3.54(11.50) 0.33 (13.27) 0.49 (12.79) 1.05 (15.46) 2.0 (−0.33, 3.8) −1.6 (−4.9, 1.7)
Tension 2.76 (2.18) 4.30 (3.75) * 4.09 (2.91) 4.05 (3.10) 0.79 (0.27, 1.3) ** −0.78 (−1.6, 0.01)
Depression 1.11 (1.90) 1.85 (3.75) 2.12 (3.88) 2.43 (3.83) 0.38 (−0.23, 1.0) −0.22 (−1.1, 0.66)
Fatigue 3.78 (3.64) 4.26 (3.54) 4.47 (4.71) 4.52 (4.19) 0.23 (−0.45, 0.91) −0.20 (−1.2, 0.78)
Anger 0.80 (1.61) 1.04 (1.69) 0.95 (2.06) 2.12 (3.49) 0.12 (−0.29, 0.53) 0.48 (−0.11, 1.1)
Confusion 4.30 (2.07) 4.63 (2.12) 4.42 (2.12) 4.64 (1.96) 0.17 (−0.20, 0.53) −0.04, (−0.56, 0.49)
Vigor 16.30 (5.66) 15.76 (5.68) 15.56 (5.33) 16.71 (6.47) −0.27 (−1.2, 0.67) 0.84 (−0.51, 2.2)
* p < 0.05, ** p < 0.01. † Models adjusted for age and sex. Pre–post data are presented as mean (SD); regression outcomes are presented as β
coefficients (95% CI).
3.5. Neurocognitive Outcomes
Pre–post comparisons showed that VOLT efficiency, N-back sensitivity, and N-back
accuracy increased in the placebo group, while VOLT efficiency, N-back sensitivity, N-back
accuracy, AM efficiency, and LOT efficiency increased in the PBB group. However, the
only significant between-group differences were in AM efficiency. There were significant
between-group effects for pre and post DSST efficiency, although this was because the
PBB group scored consistently higher than the placebo group. In linear mixed models,
the PBB group show no decline in neurocognitive outcomes when compared to placebo.
Additionally, there were significant improvements in the PBB group for PVT attentional
lapses (p = 0.035), and PVT median reaction time (p = 0.009), N-back accuracy (p = 0.044),
and BART Optimal Pumps Difference (p = 0.022). For reference, the BART Optimal Pumps
Difference refers to the number of pumps that maximizes an individual’s reward during the
task, and then measures the group differences from that optimum. Thus, the improvement
in this measure refers to participants more accurately assessing the risk of adding another
pump. These results are presented in Table 4 and in Figure 2C-F.
Table 4. Pre–post comparisons within and between groups on neurocognitive outcomes.
Placebo PBB Linear Mixed-Effects Models †
Neurocognitive Test
Battery Pre Post Pre Post Time Group by Time
MPT Score 990.48 (6.03) 991.33 (6.41) 989.93 (6.36) 991.36 (10.11) 0.34 (−1.4, 2.1) 0.32 (−2.2, 3.0)
VOLT Efficiency 587.93 (94.21) 671.63(104.59) 567.74 (102.02) 676.76 (89.48) *** 43 (30, 55) *** 11 (−6.2, 29)
N-Back Sensitivity (%) 56.09 (21.89) 67.53 (20.59) 50.55 (25.83) 71.91 (17.76) *** 5.6 (2.4, 8.7) *** 5.2 (0, 10.5)
N-Back Specificity (%) 87.47 (14.73) 92.18 (8.85) 90.60 (16.39) 94.47 (5.60) 2.4 (0.41, 4.4) * −0.48 (−3.4, 2.4)
N-Back Accuracy 440.57(228.62)
597.22
(246.46) 416.84 (251.24) 663.81 (191.34) *** 77 (46, 108) *** 48 (4.1, 92) *
AM Efficiency 535.41(102.54)
578.61
(100.63) 539.35 (98.52) 617.19 (96.48) *** 21 (6.9, 35) ** 17 (−3.0, 37)
LOT Mean Rotation
Error (%) 48.33 (19.52) 48.93 (20.83) 55.12 (22.41) 46.71 (20.68) 0.69 (−2.1, 3.5) −4.3 (−8.7, 0.15)
LOT Efficiency 776.93(117.37)
802.91
(125.64) 763.65 (100.40) 820.71 (79.08) ** 12 (−1.1, 26) 17 (−2.2, 36)
DSST Efficiency 940.48 (81.53) 954.24 (61.30) 962.70 (87.40) 980.00 (18.45) 6.9 (−2.0, 16) 1.6 (−11, 14)
BART Optimal Pumps
Difference −1.42 (0.82) −1.60 (0.80) −1.70 (0.99) −1.44 (0.89)
−0.08 (−0.19,
0.02) 0.22 (0.06, 0.37) *
BART Accuracy 873.43(147.84)
861.52
(141.57) 810.81 (181.53) 847.55 (149.21) −5.4 (−29, 18) 25 (−9.3, 59)
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Table 4. Cont.
Psychomotor Vigilance
Test Pre Post Pre Post Time Group by Time
Attentional Lapses 3.50 (2.99) 3.91 (5.60) 5.40 (8.45) 3.76 (6.93) 0.21 (−0.43, 0.85) −1.0 (−2.0, −0.12) *
Median Response Time
(ms) 228.07 (28.45) 238.95 (42.22) 256.67 (120.57) 246.44 (97.79) 5.4 (0.33, 11) * −11.0 (−18, −3.5) **
Mean Response Time
(ms) 264.11 (48.17) 262.10 (56.24) 307.55 (208.07) 265.81 (99.30) −1.0 (−17, 15) −20.0 (−43, 2.4)
* p < 0.05, ** p < 0.01, *** p < 0.001. Pre–post data are compared within-groups. † Models adjusted for sex and age with random intercepts.
Pre–post data are presented as mean (SD), while regression outcomes are presented as β-coefficients (95% CI).
4. Discussion
In this 30-day randomized double-blind placebo-controlled trial, PBB supplementation
had no significant effects on sleep onset latency or percentage of time spent in REM sleep.
However, PBB significantly improved self-reported sleep quality, sustained attention,
and insomnia symptoms. Furthermore, PBB did not adversely affect neurocognitive
functioning, and it even improved some elements of working memory, vigilant attention,
and risk assessment. These data provide promising evidence that polyphenol compounds
may improve sleep in individuals with subclinical sleep disturbances.
In contradiction to the primary study hypotheses, the use of PBB did not improve
sleep onset latency or increase the percentage of REM sleep over placebo. Although no
significant differences were noted, sleep onset latency at baseline was only 14–15 min
and tended to improve in both groups, suggesting a placebo effect. Similarly, the lack
of change in REM sleep may be due to the shorter baseline REM sleep in the placebo
group, which regressed to the mean by the trial’s end. Placebo effects are common in sleep
trials, including subjective sleep onset latency [40–42]. Additionally, post-trial interviews
revealed that participants in both groups appreciated the consistent feedback on their sleep
and used the study as a vehicle for maintaining better sleep habits.
Despite the null findings for sleep onset latency and percent REM sleep, the use of PBB
resulted in modestly improved sleep quality, sustained attention, and insomnia symptoms
over placebo. While a 1-point improvement on the ISI over the course of a month does not
appear dramatic, participants’ ISI scores were not very large to begin with (4.7 in placebo,
6.1 in PBB), and so, a 1-point reduction in the PBB group represents an improvement of
roughly 15% over baseline. At a mechanistic level, the polyphenol RA is known to de-
crease anxiogenic behavior and possibly increase endogenous GABA [16,17,25,43–47], thus
leading to improved sleep and reduced anxiety/insomnia. Similarly, EGCG is known to im-
prove mood [48], possibly through GABA-mediated inhibition [23]. These improvements in
sleep and mood may be responsible for the reduced attentional lapses and shorter response
times observed on the psychomotor vigilance task, although changes in cholinergic activity
may also have supported sustained attention.
Finally, PBB showed no adverse neurocognitive effects and may have improved
measures of vigilant attention, working memory, and risk assessment. This is notable
considering that the sample was young, healthy, and had no major sleep disorders, which
excludes several potential sources of neurocognitive impairment. On a clinical level,
improved attention and risk assessment could reduce risk of injury in everyday activities
such as driving a car, although further research would be needed to substantiate this claim.
However, the primary point in this study was that PBB did not compromise neurocognitive
functioning, which contrasts with other supplements that may improve sleep quality and
insomnia symptoms but leave users with a morning hangover and grogginess that can lead
to drowsy driving and impaired job performance. Together, these improvements in sleep
quality, insomnia symptoms, and neurocognitive functioning indicate that polyphenol
compounds could be a promising over-the-counter sleep aid to help individuals with
subclinical sleep disturbances.
This study has a number of strengths, including the rigorous study design and use of
validated measures of sleep and neurocognitive performance. Potential limitations include
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the narrow scope of trial participants, who were generally young, healthy, and free of
clinical sleep disorders or significant sleep disturbances. Another limitation is that models
were not adjusted for baseline differences in race/ethnicity and REM sleep, although the
statistical difference in the former case is minor, and in the latter was not relevant given the
null finding. Additionally, the lack of polysomnography data, which is the gold standard for
evaluating sleep architecture, severely limits inferences on the effects of PBB on REM sleep.
A further limitation is that neurocognitive testing was not conducted at a consistent time
of day across individuals, meaning the results of neurocognitive testing could have been
influenced by time-of-day testing effects. Future studies of polyphenol compounds as sleep
aids should include individuals with a broader range of sleep disturbances, particularly
older individuals, and they should compare PBB with other over-the-counter agents, such
as diphenhydramine, melatonin, or other herbal remedies.
5. Conclusions
Despite numerous validated treatments for clinical sleep disorders, there are few
effective options for individuals with subclinical sleep disturbances. Based on emerging ev-
idence that polyphenol compounds can improve sleep, this randomized placebo-controlled
trial evaluated the effects of a polyphenol blend on sleep, mood, and neurocognitive
functioning. After 30 days, supplementation with a polyphenol blend improved sleep
quality, reduced insomnia symptoms, and even improved some elements of neurocognitive
functioning over placebo. These results indicate that polyphenols may have a role in
over-the-counter treatment of subclinical sleep disturbances.
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